Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Abciximab Recombinant Human Monoclonal Antibody (7E3 (Abciximab))

Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA547865
Description
Specificity: Recognises human CD41.
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (alpha-v-beta-3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. Abciximab binds to the intact platelet GpiIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GpiIb/IIIa. By binding to the vitronectin receptor (also known as the alpha-v-beta-3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.
Specifications
| Abciximab | |
| Recombinant Monoclonal | |
| 1 mg/mL | |
| PBS with 0.02% ProClin 300 | |
| Human | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| IgG1 κ |
| Flow Cytometry, Inhibition Assays | |
| 7E3 (Abciximab) | |
| Unconjugated | |
| c7E3 | |
| CD41 is the integrin alpha chain 2b forming a fibrinogen receptor in heterodimeric complex with beta 3. | |
| 200 μg | |
| Primary | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction